< Key Hightlight >

Antibody drug conjugates are the new age therapeutic agents. These are examples of immunoconjugates and bioconjugates. They combine the unique targeting property of monoclonal antibodies and the cancer cell killing ability of cytotoxic drugs. This concept of a “magic bullet” to deliver cytotoxic therapy to the site of a tumor has been envisioned for a century. But its success has become possible only now with the recent technological advancements. The recent approvals of ADCETRIS and Kadcyla followed by various Antibody Drug Conjugates (ADCs) in pipeline highlight the potential for new therapeutic innovations in the ADC industry.

According to this edition of the report “Global Antibody Drug Conjugate Market Outlook 2020”, the ADC market is anticipated to reach around US$ 12.7 Billion by 2020. In our report, there is a detailed analysis of the market for ADCETRIS and Kadcyla. An estimation of the market potential of these drugs has been done keeping in mind that these drugs are being tested in clinical trials for various indications, apart from the ones which are already approved. The mentioned ADCs will take some time to show their complete market potential, we believe.

Moreover, in our report we have provided information about the ADCs at various stages of clinical development. We have highlighted the various cancer indications that these ADCs target and the cytotoxic drugs that are commonly used for their development. Apart from this, the study provides comprehensive analysis of various ADCs in advanced stages of development. In addition, the report highlights the major drivers and challenges, latest trends and developments and strategic collaborations impacting the industry’s growth.

The latter part of the report discusses some of the prominent players in the ADC market. A brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Moreover, comparative analyses of their strengths and weaknesses have also been done. Overall, the report will prove as a complete source of knowledge and analysis for clients and potential investors.